Lantheus (NASDAQ:LNTH) Sees Large Volume Increase – Here’s What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares saw unusually-strong trading volume on Wednesday . Approximately 822,269 shares changed hands during mid-day trading, a decline of 0% from the previous session’s volume of 824,416 shares.The stock last traded at $92.92 and had previously closed at $80.05.

Analysts Set New Price Targets

A number of research analysts recently weighed in on LNTH shares. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Up 18.1 %

The company has a market capitalization of $6.57 billion, a price-to-earnings ratio of 15.72 and a beta of 0.44. The firm’s 50 day simple moving average is $89.77 and its 200-day simple moving average is $96.81.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, February 26th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Lantheus

Several institutional investors and hedge funds have recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the third quarter worth $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $27,000. Signaturefd LLC grew its stake in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. Summit Securities Group LLC acquired a new position in Lantheus in the 4th quarter valued at $37,000. Finally, UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.